nature portfolio

Corresponding author(s):	Michael P Hart
Last updated by author(s):	2024-9-12

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~ .	100		
St	at.	ıstı	

n/a	Cor	nfirmed
	X	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	×	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	X	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
	X	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	X	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	X	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
x		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
,		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Cod	-+	vare and code

Software and code

Policy information about availability of computer code

Data collection

Code developed by Tau Scientifics to run WormWatcher was used to collect images during behavioral assays and is commercially available. No code was used in this work

Data analysis

No code was used to analyze data. Data analysis was performed manually

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>

All data that supports the findings of this study are represented in the article, tables, and figures. All data are available from the corresponding author upon request.

B 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	i i i i i i i i i i i i i i i i i i i	and the second of the second of the second		
Research involving	hiiman narticii	nante thair data	or biological	matarial
1/626a161111170171118	Hulliali baltıcı	Dants, then data	. UI DIUIUEICAI	Hiateliai

Policy information about studies with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation)</u> , <u>and sexual orientation</u> and <u>race</u> , ethnicity and <u>racism</u> .					
Reporting on sex an	d gender	no human participants, data, or biological material are included.			
Reporting on race, other socially releva		no human participants, data, or biological material are included.			
Population characteristics		no human participants, data, or biological material are included.			
Recruitment		no human participants, data, or biological material are included.			
Ethics oversight		no human participants, data, or biological material are included.			
Note that full informa	tion on the appr	oval of the study protocol must also be provided in the manuscript.			
Field-spe	cific re	porting			
Please select the or	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences	В	ehavioural & social sciences			
For a reference copy of the	he document with	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life scier	ices stu	udy design			
All studies must dis	close on these	points even when the disclosure is negative.			
Sample size	Sample sizes were chosen based on previous literature and common practices within the C. elegans field.				
Data exclusions	Data exclusions Animals were not analyzed from live imaging experiments if movement occurred during imaging. Animals were also excluded from these experiments if initial fluorescence was was not sufficiently high, making fluorescence recovery of hard to assess. Data from behavioral experiments were not included if there was bacterial contamination or other occluding factors preventing accurate counts.				
Replication	All behavioral a	nd imaging experiments were performed on at least three separate days to ensure that findings replicated			
Randomization	Different genot	ype animals were put onto the aggregation assay plate at random with experimenter blinded to genotype			
Blinding	Experimenter w	vas blinded to genotype when possible			
Reportin	g for sp	pecific materials, systems and methods			
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & exp	nerimental s	vstems Methods			
n/a Involved in th		n/a Involved in the study			
X Antibodies					
x Eukaryotic		Flow cytometry			
Palaeontology and archaeology MRI-based neuroimaging					
X Animals and other organisms X Clinical data					
	a search of concer	n			
✗ ☐ Plants	504.01.01.001.001				
— —					
Animals and	other res	earch organisms			
Policy information a Research	about <u>studies ir</u>	nvolving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in			
Laboratory animals	C. eleg	ans. All strains in the study are listed in a supplementary table with exact genotypes. Ages of animals specified in methods.			

Wild animals Study did not involve wild animals

Reporting on sex As indicated in methods, all animals were C. elegans hermaphrodites.

Field-collected samples Study does not include samples collected from the field

Ethics oversight No ethical board or approval required for invertebrate C. elegans experiments.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor

Authentication

was applied.

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.